The Pandemic Did Not Affect The Moon After All, Scientists Say
Here's the original hypothesis from last year: As businesses closed their doors in 2020 and we all spent more time at home, carbon emissions dropped and there was a drop in terrestrial radiation – the heat being generated by our planet, and taken up by the Moon.
Previous research has raised the question of terrestrial radiation influencing lunar surface temperatures – and indeed there was an observed drop in Moon nighttime temperatures across April and May 2020, when many lockdowns were in force.
In the latest study, researchers from the Missouri University of Science and Technology (Missouri S&T) and the University of West Indies (UWI) wanted to take a closer look at the data – and found some problems with the link between COVID-19 and lunar temperatures.
"The idea that our activity, or lack of activity, on Earth would have significant influence on the temperatures of the Moon – which is almost 240,000 miles from us – didn't seem likely, but we decided to keep an open mind and conduct additional research," says civil engineer William Schonberg from Missouri S&T.
Looking at the data, the researchers found some problems with the original hypothesis. First, there was a dip in lunar temperatures in 2018 similar to the one in 2020, and a steady decline from 2019 – which doesn't quite fit in with the timing of the pandemic and its lockdowns.
In fact, the temperature readings gathered by NASA's Lunar Reconnaissance Orbiter suggest cyclical fluctuations rather than one distinct dip, according to the updated analysis. The researchers also point to a 2021 study which found that any emissions reduction linked to COVID-19 only affected the lower parts of Earth's atmosphere.
"We're not disputing that the temperatures did go down at different times during the time frame studied, but it seems to be a bit of a stretch to state with any certainty that human activity was the primary cause of this," says Schonberg.
The researchers behind the new study also raise the possibility that fewer pollutants and a clearer night sky would actually increase the heat being reflected back from Earth to the Moon – potentially raising rather than reducing lunar temperatures.
There are of course a multitude of factors at play here, but the conclusion of the new study is that shifts in human activity are unlikely to have an impact on the temperatures on the Moon – during COVID-19 or any other period.
"During the Moon's nighttime, there is a small possibility that heat and radiation from Earth might have a very small effect on the lunar surface temperatures," says Schonberg.
"But this influence would probably be so minimal that it would be difficult to measure or even notice."
The research has been published in the Monthly Notices of the Royal Astronomical Society: Letters.
Scientists Simulated Bennu Crashing to Earth in September 2182. It's Not Pretty.
At 1.3 Billion Light-Years Wide, Quipu Is Officially The Biggest Thing in The Universe
Hubble Reveals Cosmic Bullet That Gave The Bullseye Galaxy Its Record-Breaking Rings
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Miami Herald
5 hours ago
- Miami Herald
Oddity from Alabama creek is tooth of dinosaur that reached 30 feet, experts say
A 'shiny' fossil found in an Alabama creek has been identified as the tooth of a large dinosaur that doesn't quite belong at the site, experts say. Hadrosaurs were land-dwellers, but the tooth surfaced in a spot that was underwater during the age of dinosaurs, according to the Alabama Museum of Natural History. The tooth was discovered in gravel by Dr. John Friel, director of the Alabama Museum of Natural History, as he accompanied a group of fossil enthusiasts to a creek about a 50-mile drive southwest from the University of Alabama campus near Tuscaloosa. 'I have been doing these trips for the past ten years, but this was the first time I have ever found a dinosaur fossil,' Friel told McClatchy News in an email. 'When I first picked it up, I thought it was just another odd piece of bone that I would not be able to identify further. However, when I turned it over and saw that it had a shiny enameled surface with a distinctive texture, I was fairly certain it was a tooth.' Two university paleontologists were included in the group that day, and both confirmed it was likely a hadrosaur tooth, he said. Technically, it's just the base of a tooth, but it is still more than a half inch long. Hadrosaurs were duck-billed herbivores that grew to about 30 to 50 feet in length, and 'had hundreds of teeth,' Fossil Era reports. They were also fast, and 'may have been able to outrun a T-rex.' It's taken educated guesswork to explain how the tooth got in the stream. The water cuts through a layer of sediment that 'formed roughly 84 million years ago when this part of Alabama was submerged under the sea,' Friel said. Visitors typically find ancient shark's teeth and internal molds of ammonites and oyster shells. 'Dinosaur fossils are very uncommon in Alabama since there are no surface deposits of Jurassic age,' Friel said. 'All of the dinosaur fossils discovered in Alabama are thought to be of dinosaurs that died and were then washed out to sea where they were likely scavenged by sharks or other marine creatures before they were fossilized.' The tooth will likely be added to the museum's research collection and could be included in a future exhibit, he said.
Yahoo
6 hours ago
- Yahoo
ScaleReady Announces a G-Rex® Grant has been awarded to Sidra Medicine
ST. PAUL, Minn., Aug. 5, 2025 /PRNewswire/ -- ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that Sidra Medicine, a women and children's hospital in Qatar, has been awarded a $100,000 G-Rex® Grant. Sidra Medicine's G-Rex® Grant will enable expeditious development, validation, and implementation of a G-Rex® centric CAR-T cell production platform. The G-Rex Grant will allow Sidra Medicine to perform the processes and preclinical development for a CD19 CAR-T cell therapy product that will initially be used in pediatric oncology settings. Sidra Medicine will also receive early access to the G-CART™ process currently in development at Cell Ready, the world's first and only G-Rex centric contract development and manufacturing organization (CDMO). The Grant will also support the implementation of fully closed system, semi-automated G-Rex production compliant with current Good Manufacturing Practices (cGMPs). Lastly, the Grant will support the technology transfer to Sidra Medicine's newly established GMP facility for qualification and implementation. "Sidra Medicine is a pioneering healthcare institution that has innovation weaved into the very core of its precision medicine program. Our GMP facility has been specifically set up to develop better treatment protocols for pediatric diseases including cancers, genetic and rare diseases. The G-Rex® Grant will play a key role in accelerating the readiness of our protocols, particularly for Sidra Medicine's pediatric oncology program. Our preliminary findings have already shown us that the G-Rex® method is outstanding in its simplicity and the unique T cell phenotype resulting from the cell culture. This methodology will allow us to implement an affordable, highly efficient G-Rex based cell manufacturing platform with the most suitable T cell phenotype, ultimately having a positive impact on pediatric patient care and cure," said Sara Deola, M.D., Ph.D., Research Investigator at Sidra Medicine. "We're eager to support the emerging Cell & Gene Therapy (CGT) industry in Qatar and the Middle East. By entering the field of CAR-T without any preconceived manufacturing notions and quickly gathering and reviewing G-Rex manufacturing data, Sidra Medicine quickly recognized the full array of advantages that our G-Rex centric manufacturing process offers relative to alternatives. Sidra Medicine's quick grasp of the technical and economic advantages of G-Rex relative to alternatives gives us confidence that this grant will set the stage for low cost and fully scalable CAR-T manufacturing in Qatar and the Middle East." said John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex. ScaleReady's G-Rex Grant Program has now surpassed $40M of no-cost product commitments to grant recipients with the goal of advancing the state of cell and gene-modified cell therapy (CGT) development and manufacturing. Individual Grant Awards are worth up to $300,000. G-Rex Grant Recipients also gain access to exclusive support from ScaleReady's growing consortium of G-Rex Grant Partners who bring best-in-class tools and technologies as well as unparalleled knowledge and expertise in the areas of cGMP manufacturing, quality and regulatory affairs, CGT business operations, and more. Importantly, ScaleReady has just introduced yet another FREE program to accelerate the universal presence of highly efficient and scalable CGT manufacturing. Under this program ScaleReady has partnered with Hanson Wade to launch an event series called LEAN Cell & Gene™. All CGT entities are invited to attend and will learn how to systematically identify and eliminate waste, stabilize business operations, increase drug product quality and supply, and develop a LEAN approach to cell and gene therapy development and manufacturing. For more information about the G-Rex® Grant Program, please contact info@ For more information about LEAN Cell & Gene™, please use this link to register for the free event series. About ScaleReadyScaleReady provides the field of cell and gene-modified cell therapy (CGT) with a G-Rex centric manufacturing platform that enables the world's most practical, flexible, scalable, and affordable CGT drug product development and manufacturing. The G-Rex manufacturing platform is currently used by a rapidly growing list of over 800 organizations and is producing drug products for approximately 50% of CGT clinical trials as well as 5 commercially approved CGT drugs. CGT entities relying on the breadth and scope of ScaleReady's expertise can expect to save years of time and millions of dollars on the path to CGT commercialization. For more information about the ScaleReady G-Rex® Grant Program, please contact info@ About Wilson Wolf ManufacturingWilson Wolf ( is dedicated to simplifying cell and gene-modified cell (CGT) therapy research, process development, and manufacturing. This is being accomplished through its scalable G-Rex technology, which is used throughout the world in CGT applications ranging from basic research to commercial drug production. Wilson Wolf's mission is to create hope for cancer patients, one G-Rex® device at a time. About Bio-Techne CorporationBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex® Bioreactors, including right-sized reagent quantities in containers that are tailored to high throughput closed-system manufacturing. For more information on Bio-Techne and its brands, please visit or follow the Company on social media at: Facebook, LinkedIn, Twitter or YouTube. Contact: David Clair, Vice President, Investor Relations & Corporate About CellReady LLCCellReady is the world's first and only G-Rex centric contract development and manufacturing organization (CDMO) specializing in G-Rex based cell and gene-modified cell therapy development and manufacturing. The company offers a wide range of services to support the development and commercialization of these therapies. CellReady's mission is to create hope for cancer patients, one G-Rex® process at a time. About Sidra Medicine Innovating Care. Transforming Lives From the heart of Qatar, Sidra Medicine, is a private, not-for-profit academic healthcare and research institution for women, children, and young people. Established by the Qatar Foundation for Education, Science, and Community Development, Sidra Medicine is committed to delivering exceptional patient and family-focused care, conducting innovative biomedical and clinical research, and providing a personalized journey of care and cure and precision medicine specifically for rare and genetic diseases. To access our specialised healthcare or international patient services, including pediatric care, women's health, and rare disease treatment or to book a consultation at one of our private clinics, please call +974 40033333 or visit our website at For more information, follow us on Facebook, Instagram, X and LinkedIn. View original content to download multimedia: SOURCE Bio-Techne Corporation
Politico
a day ago
- Politico
Experts' bird flu warning
With David Lim, Erin Schumaker and Simon Levien Driving the Day BIRD FLU LATEST — Bird flu, for the moment, appears to be under control. But experts have a warning for federal and state health officials: Fall is coming — so don't get too comfortable, Sophie and David report. Over the past few months, avian flu cases among humans, cattle and poultry have slowed — easing fears that the U.S. could be hurdling toward another major pandemic and prompting the CDC to end its emergency response. When viruses collide: Eight public health experts and two state health officials from Washington and California — two states hit especially hard by the outbreak — told POLITICO that the decision makes sense if the federal government's case count is accurate. But they warned that things could shift quickly as the weather cools off. The seasonal migration of birds and the human flu season will increase the chance of a fall influenza-bird flu mash-up, which could make it more likely that bird flu will spread among humans, the experts warned. 'The most likely scenario is that someone will get infected with both H5N1 and a seasonal flu virus, and they will swap genes, and that reassortment could kick off the next pandemic,' said Jennifer Nuzzo, a professor of epidemiology and director of the Pandemic Center at Brown University School of Public Health. And the emergency's end comes after the Trump administration canceled hundreds of millions of dollars it had awarded to Moderna to help the company develop an mRNA vaccine for flu strains with pandemic potential — including avian flu — leading some experts worried the U.S. isn't doing enough to prepare for the possibility of an avian flu outbreak. 'We are going to see another influenza pandemic, and it could be much worse than we saw with Covid, and we're not preparing for that at all,' said Dr. Michael T. Osterholm, director of the Center for Infectious Disease Research and Policy at the University of Minnesota. 'We have an opportunity with mRNA technology to make a vaccine much faster … and yet, if you look right now, we've cut all funding within the U.S. government for that type of work.' An accurate case count? The World Health Organization, the Food and Agriculture Organization of the United Nations and the World Organisation for Animal Health recently issued a joint assessment that the global public health risk of avian flu is low. The groups said their confidence in the assessment is medium, partly because there 'may be biases in surveillance, testing and reporting.' Nuzzo cautioned that hesitation among farmworkers — many of whom are undocumented — to be tested for the virus, as well as local politics, might make it more difficult to test people who've been potentially exposed to the virus in the fall. 'A matter of time': Bird flu this summer has been comparatively quieter compared with this time last year, and Nuzzo doesn't think the virus is spreading under the radar at similar levels seen last summer. But she cautioned that while it's not clear when another flu pandemic will emerge, it's only a matter of time. Three major flu pandemics struck during the 1900s, part of a pattern of recurring outbreaks throughout history. Former CDC principal deputy director Nirav Shah said increased global connectivity, the convergence of the boundaries between animals and humans, climate change and the rise of dense cities mean the number of pandemic flus in the past century should be viewed as a baseline, even though society has new treatments and other methods to intervene faster than in the past. WELCOME TO MONDAY PULSE. The Senate adjourned Saturday evening, meaning we're officially in August recess season. Send your tips, scoops and feedback to khooper@ and sgardner@ and follow along @kelhoops and @sophie_gardnerj. AROUND THE AGENCIES BLUE STATE REBUTTAL — Blue states filed a brief Friday opposing the Trump administration's request to the Supreme Court for relief from a lower court's order, Erin reports. That order had blocked the administration from cutting grants related to diversity, equity and inclusion from the National Institutes of Health. 'The only unlawful decisions here are the federal government's,' the brief says. 'The only urgency is that manufactured by NIH in its haste to implement its unprecedented and unreasoned policies. The government has not shown any need for a stay.' In addition to being unnecessary, plaintiffs argued a stay would harm universities and institutions in their states and could hurt the public if, for example, clinical trials are canceled. Plaintiff states included Arizona, California, Colorado, Delaware, Hawaii, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New Mexico, New York, Oregon, Rhode Island, Washington, and Wisconsin. The administration requested relief last week on the grounds that the federal government shouldn't be required to pay for research not aligned with President Donald Trump's executive orders and his administration's priorities. Key context: U.S. District Judge William Young ordered the administration in June to restore hundreds of scientific grants the NIH terminated this year. During a hearing on two lawsuits about grant terminations, the Massachusetts judge, a former President Ronald Reagan appointee, rebuked the administration for what he called 'appalling' and 'palpably clear' discrimination against racial minorities and LGBTQ+ Americans. Industry Intel COMMON GROUND WITH AMA — Dr. Bobby Mukkamala, the American Medical Association's new president, is seeking common ground with Health Secretary Robert F. Kennedy Jr., even as the AMA has skirmished with Kennedy over his changes at HHS, Simon reports. Mukkamala told POLITICO on Friday he supports Kennedy's push to swap out unhealthy food additives, like Coca-Cola's decision to replace high-fructose corn syrup with cane sugar in its soda recipe. He added that he wants to prevent food producers from 'dictating' Americans' diets. Mukkamala, an otolaryngologist, has a background in lifestyle medicine, which lines up with Kennedy's interest in preventive care. But Mukkamala, who has been gearing up for his role for several months, said he hasn't met or spoken with the secretary. He earlier sent two letters to Kennedy on his personal letterhead that he described as entreaties to find common ground upon his appointment as secretary. His letters went unanswered, Mukkamala said at the Asian American Journalists Association conference in Seattle on Friday. Kennedy has been critical of the AMA, arguing it doesn't have patients' best interests in mind, as the group has pushed back and argued that the secretary has devalued expertise in HHS ranks. The doctors' group criticized the purge of experts from a vaccine safety panel and warned gravely about a similar dismissal Kennedy might take against an HHS preventative care task force. Mukkamala, in his AAJA session, was also skeptical of Susan Monarez, the first nonphysician to lead the CDC in decades after her confirmation Tuesday. 'To have someone that is a medical doctor is critically important,' he said. 'And you put them in a position like that, you have to wonder, how good are they going to be at that, right?' Monarez earned a doctorate in microbiology and immunology and was deputy director of ARPA-H, the agency former President Joe Biden created several years ago to invest in high-risk, high-reward research. Public Health NEW KENNEDY OP-ED — On Friday afternoon, HHS Secretary Robert F. Kennedy Jr. took to a publication called Trial Site News — a website that often publishes anti-vaccine activists — to criticize a recent study by Danish researchers that found no harms associated with exposure to low amounts of aluminum through early childhood vaccinations. Before Kennedy became health secretary, he spread misinformation about vaccines and co-founded the Children's Health Defense, an anti-vaccine group. The study, published in the Annals of Internal Medicine in July, used nationwide registry data of more than 1,000,000 children to look for links between aluminum exposure and 50 chronic disorders, including autism. Kennedy argues that the study's design makes its results unreliable, including the decision to exclude children diagnosed with certain congenital or preexisting conditions from the study. 'The architects of this study meticulously designed it not to find harm,' Kennedy writes. 'From the outset, Andersson et al. excluded the very children most likely to reveal injuries associated with high exposures to aluminum adjuvants in childhood vaccines.' The study's first author did not respond to a request for comment. The findings largely align with other studies that have found no evidence linking vaccines to autism or other neurological conditions. WHAT WE'RE READING POLITICO's Samuel Benson reports that West Virginia schools have banned certain artificial food dyes. CBS News' Kaia Hubbard reports on CMS Administrator Mehmet Oz announcing applications for the rural hospital fund will go out in early September.
